Literature DB >> 1659051

High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity.

E Gönczöl1, C deTaisne, G Hirka, K Berencsi, W C Lin, E Paoletti, S Plotkin.   

Abstract

The human cytomegalovirus (HCMV), Towne strain, glycoprotein B (gB) gene was cloned into a vaccinia vector (Copenhagen strain) under the control of the H6 early and late vaccinia promoters (Vac-gB recombinant). The gB protein was expressed in a high percentage of the Vac-gB-infected cells throughout the virus replication cycle. Cytosine-arabinoside (ara-C) did not influence the expression of the gB protein early after infection (5 h), but did inhibit it later in viral replication (7-29 h). The Vac-gB recombinant induced HCMV neutralizing antibodies in guinea-pigs. Cells infected with the Vac-gB recombinant absorbed 50-88% of neutralizing activity of human sera obtained from volunteers previously inoculated with the Towne or Toledo strains and from naturally seropositive individuals.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1659051     DOI： 10.1016/0264-410x(91)90187-b

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  9 in total

1.  Stanley Plotkin: the bright spark of cytomegalovirus vaccines.

Authors:  Edward S Mocarski
Journal:  Med Microbiol Immunol       Date:  2015-03-20       Impact factor: 3.402

2.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

3.  A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.

Authors:  Michael A McVoy; Ronzo Lee; Frances M Saccoccio; Jukka Hartikka; Larry R Smith; Rohit Mahajan; Jian Ben Wang; Xiaohong Cui; Stuart P Adler
Journal:  Vaccine       Date:  2015-10-24       Impact factor: 3.641

Review 4.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

5.  Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L.

Authors:  Li He; Scott Taylor; Catherine Costa; Irene Görzer; Julia Kalser; Tong-Ming Fu; Daniel Freed; Dai Wang; Xiaohong Cui; Laura Hertel; Michael A McVoy
Journal:  Viruses       Date:  2022-07-09       Impact factor: 5.818

6.  Novel microneutralization assay for HCMV using automated data collection and analysis.

Authors:  Anna Maria Abai; Larry R Smith; Mary K Wloch
Journal:  J Immunol Methods       Date:  2007-02-23       Impact factor: 2.303

Review 7.  Controlling cytomegalovirus: helping the immune system take the lead.

Authors:  Patrick J Hanley; Catherine M Bollard
Journal:  Viruses       Date:  2014-05-27       Impact factor: 5.048

8.  Association of human cytomegalovirus (HCMV) neutralizing antibodies with antibodies to the HCMV glycoprotein complexes.

Authors:  Miho Shibamura; Tomoki Yoshikawa; Souichi Yamada; Takuya Inagaki; Phu Hoang Anh Nguyen; Hikaru Fujii; Shizuko Harada; Shuetsu Fukushi; Akira Oka; Masashi Mizuguchi; Masayuki Saijo
Journal:  Virol J       Date:  2020-08-03       Impact factor: 4.099

9.  The Detection of CMV in Saliva Can Mark a Systemic Infection with CMV in Renal Transplant Recipients.

Authors:  Shelley Waters; Silvia Lee; Megan Lloyd; Ashley Irish; Patricia Price
Journal:  Int J Mol Sci       Date:  2019-10-22       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.